Trial reportRespiratory research2019
Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
Trial report in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control
Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed Obstruction
Novel Insight in pathologiCal and clinicAl Attributes in Response to mepoLizumab Treatment in Patients With Chronic rhInosinusitis With Nasal pOlyPs With or Without bronchIal Asthma on a Long-term Basis (CALIOPI STUDY)
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.Respiratory research · 2021Pooled it
- Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.Respiratory research · 2021Pooled it
- Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.Respiratory research · 2021Trial
- Relationship between asthma, obesity and other comorbidities: the Australasian Severe Asthma Registry.Respiratory research · 2026Article
- The Impact of BMI on the Effect of Biologic Agents for Severe Asthma.Pulmonary therapy · 2026Review
- Respiratory Biologics Utilization, Prescription Predictors, and Outcomes in Patients With Asthma and Comorbid Overweight or Obesity.The journal of allergy and clinical immunology. In practice · 2026Observational
- Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.The European respiratory journal · 2026Review
- The Impact of Obesity on Airway Inflammation, Lung Function and Biologic Treatment in Asthma: A Narrative Review.Journal of inflammation research · 2026Review
- Obesity: Next game changer of allergic airway diseases?Clinical and translational medicine · 2025Review
- Study protocol for a randomized double-blinded placebo-controlled trial on mepolizumab for patients with chronic rhinosinusitis with nasal polyps, NSAID exacerbated respiratory disease and asthma.Frontiers in allergy · 2025Article
- Serum and urine eosinophil-derived neurotoxin (EDN) levels predict biologic response in severe asthma.The World Allergy Organization journal · 2025Article
- Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.American journal of respiratory and critical care medicine · 2024Review
- Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity.Current allergy and asthma reports · 2024Review
- Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab.Biomedicines · 2024Article
- Clinical characteristics and cytokine profiles of adult obese asthma with type2 inflammation.Scientific reports · 2023Article
- Therapeutic Potential of Combining IL-6 and TNF Blockade in a Mouse Model of Allergic Asthma.International journal of molecular sciences · 2022Article
- Recent developments in the management of severe asthma.Breathe (Sheffield, England) · 2022Article
- Different Phenotypes in Asthma: Clinical Findings and Experimental Animal Models.Clinical reviews in allergy & immunology · 2022Review
- Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.Journal of asthma and allergy · 2022Article
- Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI).
methodsThis was a post hoc individual patient-level meta-analysis of data from the Phase 3 studies MENSA (MEA115588/NCT01691521) and MUSCA (200862/NCT02281318). Patients aged ≥12 years with severe eosinophilic asthma and a history of exacerbations were randomised to 4-weekly placebo, mepolizumab 75 mg intravenously (IV) or 100 mg SC (MENSA) or placebo or mepolizumab 100 mg SC (MUSCA) for 32 (MENSA) or 24 (MUSCA) weeks. The primary endpoint was the annual rate of clinically significant exacerbations; other outcomes included the proportion of patients with no exacerbations, lung function, St George's Respiratory Questionnaire (SGRQ) and Asthma Control Questionnaire-5 (ACQ-5) scores and blood eosinophil counts. Analyses were performed by baseline body weight and BMI (≤60, > 60-75, > 75-90, > 90, < 100, ≥100 kg; ≤25, > 25-30, > 30, < 36, ≥36 kg/m
resultsOverall, 936 patients received placebo or mepolizumab 100 mg SC. Across all body weight/BMI categories, mepolizumab reduced the rate of clinically significant exacerbations by 49-70% versus placebo. Improvements with mepolizumab versus placebo were also seen in lung function in all body weight/BMI categories except > 90 kg; improvements in SGRQ and ACQ-5 scores were seen across all categories.
conclusionsMepolizumab 100 mg SC has consistent clinical benefits in patients with severe eosinophilic asthma across a range of body weights and BMIs. Data show that the fixed-dose regimen of mepolizumab is suitable, without the need for weight-based dosing.
trial registrationThis manuscript is a post hoc meta-analysis of data from the Phase 3 studies MENSA and MUSCA. ClinicalTrials.gov, NCT01691521 (MEA115588; MENSA). Registered September 24, 2012. ClinicalTrials.gov, NCT02281318 (200862; MUSCA). Registered November 3, 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.